Reduced burden of diabetes and improved quality of life: Experiences from unrestricted day-and-night hybrid closed-loop use in very young children with type 1 diabetes
Gianluca Musolino, Klemen Dovc, Charlotte K Boughton, Martin Tauschmann, Janet M Allen, Katrin Nagl, Maria Fritsch, James Yong, Emily Metcalfe, Dominique Schaeffer, Muriel Fichelle, Ulrike Schierloh, Alena G Thiele, Daniela Abt, Harald Kojzar, Julia K Mader, Sonja Slegtenhorst, Nicole Ashcroft, Malgorzata E Wilinska, Judy Sibayan, Nathan Cohen, Craig Kollman, Sabine E Hofer, Elke Fröhlich-Reiterer, Thomas M Kapellen, Carlo L Acerini, Carine de Beaufort, Fiona Campbell, Birgit Rami-Merhar, Roman Hovorka, Kidsap Consortium, Gianluca Musolino, Klemen Dovc, Charlotte K Boughton, Martin Tauschmann, Janet M Allen, Katrin Nagl, Maria Fritsch, James Yong, Emily Metcalfe, Dominique Schaeffer, Muriel Fichelle, Ulrike Schierloh, Alena G Thiele, Daniela Abt, Harald Kojzar, Julia K Mader, Sonja Slegtenhorst, Nicole Ashcroft, Malgorzata E Wilinska, Judy Sibayan, Nathan Cohen, Craig Kollman, Sabine E Hofer, Elke Fröhlich-Reiterer, Thomas M Kapellen, Carlo L Acerini, Carine de Beaufort, Fiona Campbell, Birgit Rami-Merhar, Roman Hovorka, Kidsap Consortium
Abstract
Objective: To evaluate the experiences of families with very young children aged 1 to 7 years (inclusive) with type 1 diabetes using day-and-night hybrid closed-loop insulin delivery.
Methods: Parents/caregivers of 20 children aged 1 to 7 years with type 1 diabetes completed a closed-loop experience survey following two 3-week periods of unrestricted day-and-night hybrid closed-loop insulin therapy using Cambridge FlorenceM system at home. Benefits, limitations, and improvements of closed-loop technology were explored.
Results: Responders reported reduced burden of diabetes management, less time spent managing diabetes, and improved quality of sleep with closed-loop. Ninety percent of the responders felt less worried about their child's glucose control using closed-loop. Size of study devices, battery performance and connectivity issues were identified as areas for improvement. Parents/caregivers wished for more options to input information to the system such as temporary glucose targets.
Conclusions: Parents/caregivers of very young children reported important quality of life benefits associated with using closed-loop, supporting adoption of this technology in this population.
Keywords: artificial pancreas; closed-loop insulin delivery; type 1 diabetes; very young children.
Conflict of interest statement
M.T. reports having received speaker honoraria from Minimed Medtronic and Novo Nordisk. M.Fr. has received speaker honoraria from Minimed Medtronic and has served on advisory boards for Eli Lilly. J.K.M. is a member in the advisory board of Becton‐Dickinson, Boehringer Ingelheim, Eli Lilly, Medtronic and Sanofi, and has received speaker honoraria from Abbott Diabetes Care, Astra Zeneca, Eli Lilly, Nintamed, Novo Nordisk, Roche Diabetes Care, Sanofi, Servier, and Takeda. M.E.W. has received license fees from Becton‐Dickinson and has served as a consultant to Beckton‐Dickinson. S.E.H. declares speaker honoraria from Eli Lilly and Sanofi. E.F.R. reports having received speaker honoraria from Minimed Medtronic and Eli Lilly, serving on advisory boards for Eli Lilly. T.M.K. has received speaker honoraria from Minimed Medtronic, Roche, and Eli Lilly and is member of an advisory board for Abbott Diabetes Care. C.dB. has received speaker honoraria from Minimed Medtronic, and is member of their European Psychology Advisory Board. F.C. does attend Advisory Boards and obtain speaking fees for Abbott, Medtronic, Lilly, and NovoNordisk. B.R.M. reports having received speaker honoraria from Minimed Medtronic, Eli Lilly, Roche, Menarini, and Novo Nordisk, serving on advisory boards for Eli Lilly. R.H. reports having received speaker honoraria from Minimed Medtronic, Eli Lilly, BBraun, and Novo Nordisk, serving on advisory panel for Eli Lilly, receiving license fees from BBraun and Medtronic; and having served as a consultant to BBraun, Sanofi‐Aventis, and Profil. R.H. and M.E.W. report patents and patent applications. G.M., K.D., C.B., J.M.A., K.N., J.Y., E.M., D.S., M.Fi., U.S., A.G.T., D.A., H.K., S.S., N.A., J.S., N.C., C.K., and C.L.A. declare no competing financial interests exist.
© 2019 The Authors. Pediatric Diabetes published by John Wiley & Sons Ltd.
References
- Davis EA, Keating B, Byrne GC, Russell M, Jones TW. Hypoglycemia: incidence and clinical predictors in a large population‐based sample of children and adolescents with IDDM. Diabetes Care. 1997;20(1):22‐25.
- Monaghan MC, Hilliard ME, Cogen FR, Streisand R. Nighttime caregiving behaviors among parents of young children with type 1 diabetes: associations with illness characteristics and parent functioning. Fam Syst Health. 2009;27(1):28‐38.
- Tupola S, Rajantie J, Akerblom HK. Experience of severe hypoglycaemia may influence both patient's and physician's subsequent treatment policy of insulin‐dependent diabetes mellitus. Eur J Pediatr. 1998;157(8):625‐627.
- Tauschmann M, Allen JM, Nagl K, et al. Home use of day and night hybrid closed loop insulin delivery in very young children: a multicenter 3‐week, randomized trial. Diabetes Care. 2019;42(4):594‐600. 10.2337/dc18-1881.
- Farrington C. Psychosocial impacts of hybrid closed‐loop systems in the management of diabetes: a review. Diabet Med. 2018;35(4):436‐449.
- Barnard KD, Wysocki T, Ully V, et al. Closing the loop in adults, children and adolescents with suboptimally controlled type 1 diabetes under free living conditions: a psychosocial substudy. J Diabetes Sci Technol. 2017;11(6):1080‐1088.
- Barnard KD, Wysocki T, Allen JM, et al. Closing the loop overnight at home setting: psychosocial impact for adolescents with type 1 diabetes and their parents. BMJ Open Diabetes Res Care. 2014;2(1):e000025.
- Troncone A, Bonfanti R, Iafusco D, et al. Evaluating the experience of children with type 1 diabetes and their parents taking part in an artificial pancreas clinical trial over multiple days in a diabetes camp setting. Diabetes Care. 2016;39(12):2158‐2164.
- Lee JM, Newman MW, Gebremariam A, et al. Real‐world use and self‐reported health outcomes of a patient‐designed do‐it‐yourself Mobile technology system for diabetes: lessons for Mobile health. Diabetes Technol Ther. 2017;19(4):209‐219.
Source: PubMed